Personalized ovarian cancer vaccines spark immunity in phase 1 trial

AI Summary

Researchers reported that personalized ovarian cancer vaccines produced immune responses in a phase 1 trial. The vaccines are designed to target neoantigens unique to each patient's cancer, with the aim of preventing recurrence after treatment.

Rapidly dividing cancer cells can develop DNA mutations that produce abnormal proteins called antigens, which are unique to each patient's cancer. Scientists are now testing personalized cancer vaccines that target these neoantigens and prevent cancer from returning after treatment.